Adverse reactions to targeted and non-targeted chemotherapeutic drugs with emphasis on hypersensitivity responses and the invasive metastatic switch

Cancer and Metastasis Reviews

Volumn 32, Issue 3-4, 2013, Pages 723-761

  Baldo, Brian A ^a,b,c   Pham, Nghia H ^a,b  

^a ROYAL NORTH SHORE HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c NONE   (Australia)

Author keywords

Cancer drug adverse effects; Cancer drug hypersensitivities; Chemotherapy induced hypersensitivities; Drug allergies; Drug hypersensitivities; Drugs and metastatic switch; Hypersensitivities to chemotherapy drugs

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; HISTONE DEACETYLASE INHIBITOR; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PLATELET DERIVED ENDOTHELIAL CELL GROWTH FACTOR INHIBITOR; PROTEASOME INHIBITOR; PROTEIN SERINE THREONINE KINASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR;

ANEMIA; ARTICLE; BLOOD VESSEL INJURY; CANCER CHEMOTHERAPY; DRUG CYTOTOXICITY; DRUG TARGETING; HEMATOPOIESIS; HUMAN; HYPERSENSITIVITY; LIVER INJURY; LUNG DISEASE; LUNG INJURY; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; MOLECULARLY TARGETED THERAPY; NEUTROPENIA; PRIORITY JOURNAL; RASH; THROMBOCYTOPENIA; VASCULAR DISEASE;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTOKINES; DESENSITIZATION, IMMUNOLOGIC; DRUG HYPERSENSITIVITY; HUMANS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASMS; PREMEDICATION; TUMOR BURDEN; TUMOR LYSIS SYNDROME;

EID: 84890313757     PISSN: 01677659     EISSN: 15737233     Source Type: Journal    
DOI: 10.1007/s10555-013-9447-3     Document Type: Article

References (293)

1. World Health Organization. (1972). International drug monitoring: the role of national centres. WHO Technical Report Series, no. 498, pp. 1-25.
2. Edwards, I. R., & Aronson, J. K. (2000). Adverse drug reactions: definitions, diagnosis, and management. Lancet, 356(9237), 1255-1259.
3. What is a serious event? http:/www.fda.gov/safety/medwatch/howtoreport/ ucm053087.htm. Accessed 18 February 2013.
4. Meyer, U. A. (2000). Pharmacogenetics and adverse drug reactions. Lancet, 356(9237), 1667-1671.
5. Coombs, R. R. A., & Gell, P. G. H. (1975). Classification of allergic reactions responsible for clinical hypersensitivity and disease. In P. G. H. Gell, R. R. A. Coombs, & P. J. Lachmann (Eds.), Clinical aspects of immunology (pp. 761-781). Oxford: Blackwell.
6. Johansson, S. G. O., O'B Hourihane, J., Bousquet, J., Bruijnzeel-Koomen, C., Dreborg, S., Haahtela, T., et al. (2001). A revised nomenclature for allergy: an EAACI position statement from the EAACI task force. Allergy, 56(9), 813-824.
7. Johansson, S. G. O., Bieber, T., Dahl, R., Friedmann, P. S., Lanier, B. Q., Lockey, R. F., et al. (2004). Revised nomenclature for allergy for global use: report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. The Journal of Allergy and Clinical Immunology, 113(5), 832-836.
8. Brockow, K., Romano, A., Aberer, W., Bircher, A. J., Barbaud, A., Bonadonna, P., et al. (2009). Skin testing in patients with hypersensitivity reactions to iodinated contrast media - a European multicenter study. Allergy, 64(2), 234-241.
9. Vane, J. R. (1976). The mode of action of aspirin and similar compounds. The Journal of Allergy and Clinical Immunology, 58(6), 691-712.
10. Ardavanis, A., Tryfonopoulos, D., Yiotis, I., Gerasimidis, G., Baziotis, N., & Rigatos, G. (2004). Non-allergic nature of docetaxel-induced acute hypersensitivity reactions. Anti-Cancer Drugs, 15(6), 581-585.
11. Weiss, R. B., & Baker, J. R., Jr. (1987). Hypersensitivity reaction from antineoplastic agents. Cancer and Metastasis Review, 6(3), 413-432.
12. Freter, C. E., & Perry, M. C. (2008). Systemic therapies. In M. D. Abeloff, J. O. Armitage, J. E. Niederhuber, et al. (Eds.), Clinical oncology, vol 1 (4th ed., pp. 453-463). Philadelphia: Churchill-Livingstone Elsevier.
13. National Cancer Institute (NCI) Drug Dictionary. Available at www.cancer.gov/drugdictionary. Accessed 18 February 2013.
14. List of anti-cancer drugs approved by the FDA. Available at http://pharmaknow.com/list-of-anti-cancer-drugs-aproved-by-the-fda/ (accessed February 18, 2013).
15. Thurston, D. E. (2007). Chemistry and pharmacology of anticancer drugs (pp. 29-156). Boca Raton: CRC.
16. Levitski, A., & Klein, S. (2010). Signal transduction therapy of cancer. Molecular Aspects Medicine, 31(4), 287-329.
17. Maltzman, J. D., & Millar, L. B. (2013). Chemotherapy primer: Why? What? and How? http://www.oncolink.org/treatment/article.cfm?id=224&s= 9&c=2. Accessed 18 June 2013.
18. Weiss, R. B., & Bruno, S. (1981). Hypersensitivity reactions to cancer chemotherapeutic agents. Annals of Internal Medicine, 94(1), 66-72.
19. Gonzalez, I. D., Saez, R. S., Rodilla, E. M., Yges, E. L., & Toledano, F. L. (2000). Hypersensitivity reactions to chemotherapy drugs. Alegologia et Immunologia Clinica, 15, 161-181.
20. Crestani, B., Jaccard, A., Israel-Biet, D., Couderc, L. J., Frija, J., & Clauvel, J. P. (1994). Chlorambucil-associated pneumonitis. Chest, 105(2), 634-636.
21. Kingsley, C. D. (2008). Hypersensitivity reactions. In M. C. Perry (Ed.), The chemotherapy source book (4th ed., pp. 152-173). Philadelphia: Lippincott Williams & Wilkins.
22. Komamura, H., Higashiyama, M., Hashimoto, K., Takeda, K., Kimura, H., Tani, Y., et al. (1995). Three cases of chemotherapy-induced acral erythema. The Journal of Dermatology, 22(2), 116-121.
23. Popescu, N. A., Sheehan, M. G., Kouides, P. A., Loughner, J. E., Condemi, J. A., Looney, R. J., et al. (1996). Allergic reactions to cyclophosphamide: delayed clinical expression associated with positive immediate skin-tests to drug metabolites in five patients. Journal of Allergy and Clinical Immunology, 97(1, pt 1), 26-33.
24. Pagani, M. (2010). The complex clinical picture of presumably allergic side effects to cytostatic drugs: symptoms, pathomechanism, reexposure, and desensitization. Medical Clinics of North America, 94(4), 835-852.
25. Klastersky, J. (2003). Side effects of ifosfamide. Oncology, 65(Suppl 2), 7-10.
26. Estève, E., Bagot, M., Joly, P., Souteyrand, P., Beylot-Barry, M., Vaillant, L., et al. (1999). A prospective study of cutaneous intolerance to topical mechlorethamine therapy in patients with cutaneous T-cell lymphomas. Archives of Dermatology, 135(11), 1349-1353.
27. Cornwell, G. G., Pajak, T. F., & McIntyre, O. R. (1979). Hypersensitivity reactions to iv melphalan during treatment of multiple myeloma: cancer and leukemia group B experience. Cancer Treatment Reports, 63(3), 399-403.
28. Weiss, R. B. (1992). Hypersensitivity reactions. Seminars in Oncology, 19(5), 458-477.
29. Chang, P., Riggs, C. E., Scheerer, M. T., Wiernik, P. H., & Bachur, N. R. (1976). Combination chemotherapy with adriamycin and streptozocin. II. Clinicopharmacologic correlation of augmented adriamycin toxicity caused by streptozocin. Clinical Pharmacology and Therapeutics, 20(5), 611-616.
30. McClay, E., Lusch, C. J., & Mastrangelo, M. J. (1987). Allergy-induced hepatic toxicity associated with dacarbazine. Cancer Treatment Reports, 71(2), 219-220.
31. Koschel, D., Handzhiev, S., Leucht, V., Holotiuk, O., Fisseler-Eckhoff, A., & Höffken, G. (2009). Hypersensitivity pneumonitis associated with the use of temozolomide. European Respiratory Journal, 33(4), 931-934.
32. Alonso-Llamazares, A., Vega-Castro, A., Beitia-Mazuecos, J. M., Mateo-Borrega, B., & Cardenas-Contreras, R. (2012). Rapid desensitization with temozolomide in patients with delayed maculopapular rash. Journal of Investigational Allergology and Clinical Immunology, 22(6), 437-459.
33. National Library Medicine HSDB database (2013). Toxnet toxicology data network. Altretamine. http://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb: @term+@DOCNO+7559. Accessed 19 February 2013.
34. Lee, M., & Sharifi, R. (1987). Generalized hypersensitivity reaction to intravenous thiotepa and doxorubicin. Journal of Urology, 138(1), 143-144.
35. Liu, C. Y. (2002). Fluorouracil for allergic reactions to capecitabine. Annals of Pharmacotherapy, 36(12), 1897-1899.
36. Mignogna, M. D., Fortuna, G., Falleti, J., & Leuci, S. (2009). Capecitabine-induced stomatitis: a likely pathogenetic mechanism of oral lichenoid mucositis. European Journal of Clinical Pharmacology, 65(10), 1057-1059.
37. Crawford, J. H., Eikelboom, J. W., & McQuillan, A. (2002). Recurrent palmar-plantar erythrodysesthesia following high-dose cytarabine treatment for acute lymphoblastic leukemia. European Journal of Haematology, 69(5-6), 315-317.
38. O'Brien, M. E. R., & Souberbielle, B. E. (1992). Allergic reactions to cytotoxic drugs - an update. Annals of Oncology, 3(8), 605-610.
39. Kudrik, F. J., Rivera, M. P., Molina, P. L., Maygarden, S., & Socinski, M. A. (2002). Hypersensitivity pneumonitis in advanced non-small-cell lung cancer patients receiving gemcitabine and paclitaxel: report of two cases and review of the literature. Clinical Lung Cancer, 4(1), 52-56.
40. Jeter, M. D., Jänne, P. A., Brooks, S., Burstein, H. J., Wen, P., Fuchs, C. S., et al. (2002). Gemcitabine-induced radiation recall. International Journal of Radiation Oncology, Biology, Physics, 53(2), 394-400.
41. Meunier, P., Castaigne, S., Bastie, J. N., Chosidow, O., & Aractingi, S. (1996). Cutaneous reaction after treatment with 2-chlorodeoxyadenosine. Acta Dermato Venereologica, 76(5), 385-386.
42. Robak, T., Blasinska-Morawiec, M., Krykowski, E., Hellmann, A., & Konopka, L. (1997). Autoimmune haemolytic anemia in patients with chronic lymphocytic leukemia treated with 2-chlorodeoxyadenosine (clidribine). European Journal of Haematology, 58(2), 109-113.
43. Longo, G., Gandini, G., Ferrara, L., Torelli, U., & Emilia, G. (1997). Fludarabine and autoimmune hemolytic anemia in chronic lymphocytic leukemia. European Journal of Haematology, 59(2), 124-125.
44. Korelitz, B. I., Zlatanic, J., Goel, F., & Fuller, S. (1999). Allergic reactions to 6-mercaptopurine during treatment for inflammatory bowel disease. Journal of Clinical Gastroenterology, 28(4), 341-344.
45. O'Dwyer, P. J., King, S. A., Eisenhauer, E., Grem, J. L., & Hoth, D. F. (1989). Hypersensitivity reactions to deoxycoformycin. Cancer Chemotherapy and Pharmacology, 23(3), 173-175.
46. Byrd, J. C., Hertler, A. A., Weiss, R. B., Freiman, J., Kweder, S. L., & Diehl, L. F. (1995). Fatal recurrence of autoimmune hemolytic anemia following pentostatin therapy in a patient with a history of fludarabine-associated hemolytic anemia. Annals of Oncology, 6(3), 300-301.
47. White, D. A., Rankin, J. A., Stover, D. E., Gellene, R. A., & Gupta, S. (1989). Methotrexate pneumonitis. Bronchoalveolar lavage findings suggest an immunological disorder. The American Review of Respiratory Disease, 139(1), 18-21.
48. Lopes, G., Vincek, V., & Raez, L. E. (2006). Pemetrexed-associated urticarial vasculitis. Lung Cancer, 51(2), 247-249.
49. Tummino, C., Barlesi, F., Tchouhadjian, C., Tasei, A. M., Gaudy-Marqueste, C., Richard, M. A., et al. (2007). Severe cutaneous toxicity after permetrexed as second line treatment for a refractory non small cell lung cancer. [Article in French]. Revue des Maladies Respiratoires, 24(5), 635-638.
50. Dyke, R. W. (1984). Acute bronchospasm after vinca alkaloids in patients previously treated with mitomycin. The New England Journal of Medicine, 310(6), 389.
51. Rivera, M. P., Kris, M. G., Gralla, R. J., & White, D. A. (1995). Syndrome of acute dyspnea related to combined mitomycin plus vinca alkaloid chemotherapy. American Journal of Clinical Oncology, 18(3), 245-250.
52. Imai, C., Uno, K., Kakihara, T., Tanaka, A., & Uchiyama, M. (2001). Vincristine-induced fever in a child with rhabdomyosarcoma: cellular hypersensitivity to vincristine demonstrated by leukocyte migration test. Journal of Pediatric Hematology/Oncology, 23(1), 73-74.
53. Serieix, M. E., Debure, C., Baudot, N., Dubertret, L., Roux, M.-E., Morel, P., et al. (1999). Leg ulcers and hydroxyurea: forty-one cases. Archives of Dermatology, 135(7), 818-820.
54. Sandhu, H. S., Barnes, P. J., & Hernandez, P. (2000). Hydroxyurea-induced hypersensitivity pneumonitis: a case report and literature review. Canadian Respiratory Journal, 7(6), 491-495.
55. Markman, M., Kennedy, A., Webster, K., Elson, P., Peterson, G., Kulp, B., et al. (1999). Clinical features of hypersensitivity reactions to carboplatin. Journal of Clinical Oncology, 17(4), 1141-1145.
56. Randall, J. M., Bharne, A. A., & Bazhenova, L. A. (2012). Hypersensitivity reactions to carboplatin and cisplatin in non-small cell lung cancer. Journal of Thoracic Disease. doi: 10.3978/j.issn.2072-1439.2012.06.12.
57. Makrilia, N., Syrigou, E., Kaklamanos, I., Manolopoulos, L., & Wasif Saif, M. (2010). Hypersensitivity reactions associated with platinum antineoplastic agents: a systematic review. Metal-Based Drugs, Article ID 207084, 11 pp. doi: 10.1155/2010/207084.
58. Curtis, B. R., Kaliszewski, J., Marques, M. B., Wasif Saif, M., Nabelle, L., Blank, J., et al. (2006). Immune-mediated thrombocytopenia resulting from sensitivity to oxaliplatin. American Journal of Hematology, 81(3), 193-198.
59. Kunkeler, L., Nieboer, C., & Bruynzeel, P. (2000). Type III and type IV hypersensitivity reactions due to mitomycin C. Contact Dermatitis, 42(2), 74-76.
60. Janjigian, Y. Y., Lee, W., Kris, M. G., Miller, V. A., Krug, L. M., Azzoli, C. G., et al. (2010). A phase I trial of SJG-136 (NSC#694501) in advanced solid tumors. Cancer Chemotherapy and Pharmacology, 65(5), 833-838.
61. Puzanov, I., Lee, W., Chen, A. P., Calcutt, M. W., Hachey, D. L., Vermeulen, W. L., et al. (2011). Phase I, pharmacokinetic and pharmacodynamic study of SJG-136, a novel sequence selective minor groove cross-linking agent, in advanced solid tumors. Clinical Cancer Research, 17(11), 3794-3802.
62. Denschlag, D., Watermann, D., Hörig, K., Kissel, C., Tempfer, C., & Gitsch, G. (2004). Topotecan as a continuous infusion over 14 days in recurrent ovarian cancer patients. AntiCancer Research, 24(2c), 1267-1269.
63. Markman, M. (2005). Topotecan as second-line therapy for ovarian cancer: dosage versus toxicity. The Oncologist, 10(9), 695-697.
64. Merrouche, Y., Extra, J. M., Abigerges, D., Bugat, R., Catimel, G., Suc, E., et al. (1997). High dose-intensity of irinotecan administered every three weeks in advanced cancer patients: a feasibility study. Journal of Clinical Oncology, 15(3), 1080-1086.
65. Bozec, L., Bierling, P., Fromont, P., Levi, F., Debat, P., Cvitkovic, E., et al. (1997). Irinotecan-induced immune thrombocytopenia. Annals of Oncology, 9(4), 453-455.
66. Ma, D., & Isbister, J. P. (1980). Cytotoxic-induced fulminant hyperpyrexia. Cancer, 45(9), 2249-2251.
67. Chanan-Khan, A., Szebeni, J., Savay, S., Liebes, L., Rafique, N. M., Alving, C. R., et al. (2003). Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions. Annals of Oncology, 14(9), 1430-1437.
68. Taylor, W. B., Cantwell, B. M., Roberts, J. T., & Harris, A. L. (1986). Allergic reactions to mitoxantrone. Lancet, 1(8495), 1439.
69. Coppes, M. J., Jorgenson, K., & Arlette, J. P. (1997). Cutaneous toxicity following the administration of dactinomycin. Medical and Pediatric Oncology, 29(3), 226-227.
70. Tornesello, A., Piciacchia, D., Mastrangelo, S., Lasorella, A., & Mastrangelo, R. (1998). Veno-occlusive disease of the liver in right-sided Wilm's tumours. European Journal of Cancer, 34(8), 1220-1223.
71. Capelli, C., Fornari, C., De Ioris, M. A., Russo, D., & Cierico, A. (2001). An exceptional case of hypersensitivity to actinomycin D. Case report and review of the literature. [Article in Italian]. La Clinica Terapeutica, 152(5), 319-321.
72. Yamamoto, T. (2006). Bleomycin and the skin. British Journal of Dermatology, 155, 869-875.
73. Kaminskas, E., Farrell, A. T., Wang, Y. C., Sridhara, R., & Pazdur, R. (2005). FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension. The Oncologist, 10(3), 176-182.
74. Garcia-Manero, G., Gore, S. D., Cogle, C., Ward, R., Shi, T., Macbeth, K. J., et al. (2011). Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia. Journal of Clinical Oncology, 29(18), 2521-2527.
75. Giaccone, G., Rajan, A., Kelly, R. J., Gutierruz, M., Kummar, S., Yancey, M., et al. (2010). A phase I combination study of olaparib (AZD2281; KU-0059436) and cisplatin (C) plus gemcitabine (G) in adults with solid tumors. Journal of Clinical Oncology, 28(Suppl 15), 3027.
76. Kummar, S., Chen, A., Ji, J., Zhang, Y., Reid, J. M., Ames, M., et al. (2011). Phase I study of ABT-888, a PARP inhibitor, in combination with topotecan hydrochloride in adults with refractory solid tumors and lymphomas. Cancer Research, 71(17), 5626-5634.
77. Lerch, E., Györik, S., Feilchenfeldt, J., Mazzucchelli, L., & Quadri, F. (2010). A case of lenalidomide-induced hypersensitivity pneumonitis. Onkologie, 33(5), 249-252.
78. Bosulif®. FDA: full prescribing information. Adverse reactions. http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/203341lbl.pdf. Accessed 1 July 2013.
79. Gambacorti-Passerini, C., Cortes, J. E., Kim, D., Kantarjian, H., Khattry, N., Lipton, J. H., et al. (2011). Bosutinib (BOS) versus imatinib (IM) in patients (pts) with chronic phase chronic myeloid leukemia (CP CML) in the BELA trial: 18-month follow-up. Journal of Clinical Oncology, 29, abstr 6509.
80. Xalkori®. FDA: full prescribing information. Adverse reactions. http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/202570s002lbl.pdf. Accessed 1 July 2013.
81. Bang, Y. J. (2012). Treatment of ALK-positive non-small cell lung cancer. Archives of Pathology and Laboratory Medicine, 136(10), 1201-1204.
82. Sprycel®. FDA: full prescribing information. Adverse reactions. http://www.accessdata.fda.gov/drugsatfda-docs/label/2010/021986s7s8lbl.pdf. Accessed 1 July 2013.
83. Montani, D., Bergot, E., Günther, S., Savale, L., Bergeron, A., Bourdin, A., et al. (2012). Pulmonary arterial hypertension in patients treated by dasatinib. Circulation, 125(17), 2128-2137.
84. Gleevec®. FDA: full prescribing information. Adverse reactions. http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/021588s035lbl.pdf. Accessed 1 July 2013.
85. Kantarjian, H., Sawyers, C., Hochhaus, A., Guilhot, F., Schiffer, C., Gambacorti-Passerini, C., et al. (2002). Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. The New England Journal of Medicine, 346(9), 645-652.
86. Kuraishi, N., Nagai, Y., Hasegawa, M., & Ishikawa, O. (2010). Lichenoid drug eruption with palmoplantar hyperkeratosis due to imatinib mesylate: a case report and a review of the literature. Acta Dermato Venereologica, 90(1), 73-76.
87. Tasigna®. FDA: full prescribing information. Adverse reactions. http://www.accessdata.fda.gov/drugsatfda-docs/label/2010/022068s004s005lbl.pdf. Accessed 1 July 2013.
88. Iclusig®. FDA: full prescribing information. Adverse reactions. http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/203469lbl.pdf. Accessed 1 July 2013.
89. Tarceva®. FDA: full prescribing information. Adverse reactions. http://www.accessdata.fda.gov/drugsatfda-docs/label/2010/021743s14s16lbl.pdf. Accessed 1 July 2013.
90. Heidary, N., Naik, H., & Burgin, S. (2008). Chemotherapeutic agents and the skin: an update. Journal of the American Academy of Dermatology, 58(4), 545-570.
91. Iressa®. FDA: full prescribing information. Adverse reactions. http://www.accessdata.fda.gov/drugsatfda-docs/label/2005/021399s008lbl.pdf. Accessed 1 July 2013.
92. Tykerb®. FDA: full prescribing information. Adverse reactions. http://www.accessdata.fda.gov/drugsatfda-docs/label/2010/022059s007lbl.pdf. Accessed 13 July 2013.
93. Votrient®. FDA: full prescribing information. Adverse reactions. http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/022465s-010S-012lbl. pdf. Accessed 13 July 2013.
94. Stivarga®. FDA: full prescribing information. Adverse reactions. http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/203085lbl.pdf. Accessed 13 July 2013.
95. Grothey, A., Van Cutsem, E., Sobrero, A., Siena, S., Falcone, A., Ychou, M., et al. (2013). Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet, 381(9863), 303-312.
96. Arora, A., & Scholar, E. M. (2005). Role of tyrosine kinase inhibitors in cancer therapy. The Journal of Pharmacology and Experimental Therapeutics, 315(3), 971-979.
97. Nexavar®. FDA: full prescribing information. Adverse reactions. http://www.accessdata.fda.gov/drugsatfda-docs/label/2010/021923s008s009lbl.pdf. Accessed 13 July 2013.
98. Kamba, T., & McDonald, D. M. (2007). Mechanisms of adverse effects of anti-VEGF therapy for cancer. British Journal of Cancer, 96(12), 1788-1795.
99. Lee, W. J., Lee, J. L., Chang, S. E., Lee, M. W., Kang, Y. K., Choi, J. H., et al. (2009). Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib. British Journal of Dermatology, 161(5), 1045-1051.
100. Sutent®. FDA: full prescribing information. Adverse reactions. http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/021938s13s17s18lbl.pdf. Accessed 15 July 2013.
101. Vandetanib. FDA: full prescribing information. Warnings and precautions; adverse reactions. http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/ 022405s000lbl.pdf. Accessed 15 July 2013.
102. Afinitor®. FDA: full prescribing information. Adverse reactions. http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/022334s016lbl.pdf. Accessed 15 July 2013.
103. Torisel®. FDA: full prescribing information. Adverse reactions. http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/ 022088s002s004s005s007s010s012lbl.pdf. Accessed 15 July 2013.
104. Istodax®. FDA: full prescribing information. Adverse reactions. http://www.accessdata.fda.gov/drugsatfda-docs/label/2009/022393lbl.pdf. Accessed 15 July 2013.
105. Zolinza®. FDA: full prescribing information. Adverse reactions. http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/021991s002lbl.pdf. Accessed 15 July 2013.
106. Tan, J., Cang, S., Ma, Y., Petrillo, R. L., & Liu, D. (2010). Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. Journal of Hematology and Oncology, 3, 5.
107. Vesanoid®. FDA: full prescribing information. Adverse reactions. http://www.accessdata.fda.gov/drugsatfda-docs/label/2004/20438s004lbl.pdf. Accessed 15 July 2013.
108. Trisenox®. FDA: full prescribing information. Adverse reactions http://www.accessdata.fda.gov/drugsatfda-docs/label/2000/21248lbl.pdf. Accessed 19 July 2013.
109. Targretin®. FDA: full prescribing information. Adverse reactions. http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/021055s006lbl.pdf. Accessed 19 July March 2013.
110. Velcade®. FDA: full prescribing information. Adverse reactions. http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/021602s027lbl.pdf. Accessed 30 June 2013.
111. Wu, K. L., Heule, F., Lam, K., & Sonneveld, P. (2006). Pleomorphic presentation of cutaneous lesions associated with the proteasome inhibitor bortezomib in patients with multiple myeloma. Journal of the American Academy of Dermatology, 55(5), 897-900.
112. Thomas, M., Cavelier Balloy, B., Andreoli, A., Briere, J., & Petit, A. (2009). Bortezomib-induced neutrophilic dermatosis with CD30+ lymphocytic infiltration. [Article in French]. Annales de Dermatologie et de Vénéréologie, 136(5), 438-442.
113. Kyprolis®. FDA: full prescribing information. Adverse reactions. http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/202714lbl.pdf. Accessed 20 July 2013.
114. Arimidex®. FDA: full prescribing information. Adverse reactions. http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/020541s026lbl.pdf. Accessed 2 July 2013.
115. Shoda, H., Inokuma, S., Yajima, N., Tanaka, Y., & Setoguchi, K. (2005). Cutaneous vasculitis developed in a patient with breast cancer undergoing aromatase inhibition treatment. Annals of the Rheumatic Diseases, 64(4), 651-652.
116. Bremec, T., Demšar, J., Luzar, B., & Pavlović, M. D. (2009). Drug-induced pruritic micropapular eruption: anastrozole, a commonly used aromatase inhibitor. Dermatology Online Journal, 15(7), 14-16.
117. Santoro, S., Santini, M., Pepe, C., Tognetti, E., Cortelazzi, C., Ficarelli, E., et al. (2011). Aromatase inhibitor-induced skin adverse reactions: exemestane-related cutaneous vasculitis. Journal of the European Academy of Dermatology and Venereology, 25(5), 596-598.
118. Aromasin®. FDA: full prescribing information. Adverse reactions. http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/020753s009s011s012lbl. pdf. Accessed 1 July 2013.
119. Gupta, M., Vasudev, M., Thumma, S., Marks, S., Wang, Y., Blust, L., et al. (2004). Acute generalized exanthemous pustulosis (AGEP) with aromatase inhibitor (exemestane). Journal of Allergy and Clinical Immunology, 113(2), S313.
120. Femara®. FDA: full prescribing information. Adverse reactions. http://www.accessdata.fda.gov/drugsatfda-docs/label/2007/020726s014lbl.pd. Accessed 1 July 2013.
121. Zoladex®. FDA: full prescribing information. Adverse reactions. http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/019726s054, 020578s032lbl.pdf. Accessed 1 July 2013.
122. Lupron Depot®. FDA: full prescribing information. Adverse reactions. http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/020011s040lbl.pdf. Accessed 1 July 2013.
123. Shiota, M., Tokuda, N., Kanou, T., & Yamasaki, H. (2007). Incidence rate of injection-site granulomas resulting from administration of luteinizing hormone-releasing hormone analogues for the treatment of prostatic cancer. Yonsei Medical Journal, 48(3), 421-424.
124. Nolvadex®. FDA: full prescribing information. Adverse reactions. http://www.accessdata.fda.gov/drugsatfda-docs/label/2005/17970s053lbl.pdf. Accessed 1 July 2013.
125. Baptista, M. Z., Prieto, V. G., Chon, S., Hortobagyi, G. N., & Esteva, F. J. (2006). Tamoxifen-related vasculitis. Journal of Clinical Oncology, 24(21), 3504-3505.
126. Casodex®. FDA: full prescribing information. Adverse reactions. http://www.accessdata.fda.gov/drugsatfda-docs/label/2009/020498s019s021lbl.pdf. Accessed 2 July 2013.
127. Folotyn®. FDA: full prescribing information. Adverse reactions. http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/022468s003s004s005lbl. pdf. Accessed 2 July 2013.
128. Ontak®. FDA: full prescribing information. Adverse reactions. http://www.accessdata.fda.gov/drugsatfda-docs/label/2008/103767s5094lbl.pdf. Accessed 2 July 2013.
129. 389IL-2 (denileukin diftitox, Ontak®) in cutaneous T-cell lymphoma: decreased frequency and severity with steroid premedication. Clinical Lymphoma, 1(4), 298-302.
130. Polder, K., Wang, C., Duvic, M., Diwan, A. H., Parks, D., Jankov, A., et al. (2005). Toxic epidermal necrolysis associated with denileukin diftitox (DAB389IL-2) administration in a patient with follicular large cell lymphoma. Leukemia and Lymphoma, 46(12), 1807-1811.
131. Zaltrap®. FDA: full prescribing information. Adverse reactions. http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/125418s000lbl.pdf. Accessed 2 July 2013.
132. Hartley, J. A. (2011). The development of pyrrolobenzodiazepines as antitumor agents. Expert Opinion on Investigational Drugs, 20(6), 733-744.
133. Murai, J., Huang, S.-Y. N., Das, B. B., Renaud, A., Zhang, Y., Doroshow, J. H., et al. (2012). Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Research, 72(21), 5588-5599.
134. Davies, F., & Baz, R. (2010). Lenalidomide mode of action: linking bench and clinical findings. Blood Reviews, 24(Suppl 1), S13-S19.
135. Ward, H. W. C. (1973). Anti-oestrogen therapy for breast cancer: a trial of tamoxifen at two dose levels. British Medical Journal, 1(5844), 13-14.
136. Deeks, E. D., & Scott, L. J. (2009). Exemestane. Drugs, 69(7), 889-918.
137. Kotake, T., Usami, M., Akaza, H., Koiso, K., Homma, Y., Kawabe, K., et al. (1999). Goserelin acetate with or without antiandrogen or oestrogens in the treatment of patients with advanced prostate cancer: a multicenter, randomized, controlled trial in Japan. Zoladex study group. Japanese Journal of Clinical Oncology, 29(11), 562-570.
138. Fradet, Y. (2004). Bicalutamide (Casodex) in the treatment of prostate cancer. Expert Review of Anticancer Therapy, 4(1), 37-48.
139. Weinstein, I. B., & Joe, A. K. (2006). Mechanisms of disease: oncogene addiction - a rationale for molecular targeting in cancer therapy. Nature Clinical Practice Oncology, 3(8), 448-457.
140. Druker, B. J. (2008). Translation of the Philadelphia chromosome into therapy for CML. Blood, 112(13), 4808-4817.
141. Yuan, R. R., Kay, A., Berg, W. J., & Lebwohl, D. (2009). Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy. Journal of Hematology and Oncology, 2, 45-56.
142. Acharya, M. R., Sparreboom, A., Venitz, J., & Figg, W. D. (2005). Rational development of histone deacetylase inhibitors as anticancer agents: a review. Molecular Pharmacology, 68(4), 917-932.
143. Zhang, X. W., Yan, X. J., Zhou, Z. R., Yang, F. F., Wu, Z. Y., Sun, H. B., et al. (2010). Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML. Science, 328(5975), 240-243.
144. Gniadecki, R., Assaf, C., Bagot, M., Dummer, R., Duvic, M., Knobler, R., et al. (2007). The optimal use of bexarotene in cutaneous T-cell lymphoma. British Journal of Dermatology, 157(3), 433-440.
145. Zain, J., & O'Connor, O. (2010). Pralatrexate: basic understanding and clinical development. Expert Opinion on Pharmacotherapy, 11(10), 1705-1714.
146. Turturro, F. (2007). Denileukin diftitox: a biotherapeutic paradigm shift in the treatment of lymphoid-derived disorders. Expert Review of Anticancer Therapy, 7(1), 11-17.
147. Lockhart, A. C., Rothenberg, M. L., Dupont, J., Cooper, W., Chevalier, P., Sternas, L., et al. (2010). Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors. Journal of Clinical Oncology, 28(2), 207-214.
148. Tarhini, A., Frankel, P., Margolin, K. A., Chrstensen, S., Ruel, C., Shipe-Spotloe, J., et al. (2011). Aflibercept (VEGF trap) in inoperable stage III or stage IV melanoma of cutaneous or uveal origin. Clinical Cancer Research, 17(20), 6574-6581.
149. Zhao, M., & Vuori, K. (2011). The docking protein p130Cas regulates cell sensitivity to proteasome inhibition. BMC Biology, 9, 73.
150. Kisselev, A. F., van der Linden, W. A., & Overkleeft, H. S. (2012). Proteasome inhibitors: an expanding army attacking a unique target. Chemistry and Biology, 19(1), 99-115.
151. Degan, A., Alter, M., Schenck, F., Satzger, I., Völker, B., Kapp, A., et al. (2010). The hand-foot-syndrome associated with medical tumor therapy - classification and management. Journal der Deutschen Dermatologischen Gesellschaft, 8(9), 652-661.
152. Balagula, Y., Lacouture, M. E., & Cotliar, J. A. (2010). Dermatologic toxicities of targeted anticancer therapies. The Journal of Supportive Oncology, 8(4), 149-161.
153. Son, H.-S., Lee, W. Y., Lee, W.-S., Yun, S. H., & Chun, H.-K. (2009). Compliance and effective management of the hand-foot syndrome in colon cancer patients receiving capecitabine as adjuvant chemotherapy. Yonsei Medical Journal, 50(6), 796-802.
154. Gerber, P. A., Meller, S., Eames, T., Buhren, B. A., Schrumpf, H., Hetzer, S., et al. (2012). Management of EGFR-inhibitor associated rash: a retrospective study in 49 patients. European Journal of Medical Research, 17, 4. doi: 10.1186/2047-783X-17-4.
155. Lynch, T. J., Kim, E. S., Eaby, B., Garey, J., West, D. P., & Lacouture, M. E. (2007). Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. The Oncologist, 12(5), 610-621.
156. Uetrecht, J. (2007). Idiosyncratic drug reactions: current understanding. Annual Review of Pharmacology and Toxicology, 47, 513-539.
157. Diehl, L. F., & Ketchum, L. H. (1998). Autoimmune disease and chronic lymphocytic leukemia: autoimmune hemolytic anemia, pure red cell aplasia, and autoimmune thrombocytopenia. Seminars in Oncology, 25(1), 80-97.
158. Fisher, M. M., & Baldo, B. A. (1988). Acute anaphylactic reactions. Medical Journal of Australia, 149(1), 34-38.
159. Fisher, M. M., & Baldo, B. A. (1994). Anaphylaxis during anaesthesia: current aspects of diagnosis and prevention. European Journal of Anaesthesiology, 11(4), 263-284.
160. Fisher, M. M., Harle, D. G., & Baldo, B. A. (1991). Anaphylactoid reactions to narcotic analgesics. Clinical Reviews in Allergy and Immunology, 9(3-4), 309-318.
161. Mertes, P. M., Laxenaire, M. C., & Alla, F. (2003). Anaphylactic and anaphylactoid reactions occurring during anesthesia in France in 1999-2000. Anesthesiology, 99(3), 536-545.
162. Fisher, M. M., Ramakrishnan, N., Doig, G., Rose, M., & Baldo, B. (2009). The investigation of bronchospasm during induction of anaesthesia. Acta Anaesthesiologica Scandinavica, 53(8), 1006-1011.
163. Baldo, B. A., & Pham, N. H. (2012). Histamine-releasing and allergenic properties of opioid analgesic drugs: resolving the two. Anaesthesia and Intensive Care, 40(2), 216-235.
164. Garufi, C., Cristaudo, A., Vanni, B., Bria, E., Aschelter, A. M., Santucci, B., et al. (2003). Skin testing and hypersensitivity reactions to oxaliplatin. Annals of Oncology, 14(3), 497-498.
165. Pagani, M., Bonadonna, P., Senna, G. E., & Antico, A. (2008). Standardisation of skin tests for diagnosis and prevention of hypersensitivity reactions to oxaliplatin. International Archives of Allergy and Immunology, 145(1), 54-57.
166. Castells, M. C., Tennant, N. M., Sloane, D. E., Hsu, F. I., Barrett, N. A., Hong, D. I., et al. (2008). Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases. Journal of Allergy and Clinical Immunology, 122(3), 574-580.
167. Khan, A., & Hill, J. M. (1971). Atopic hypersensitivity to l-asparaginase: resistance to immunosuppression. International Archives of Allergy and Applied Immunology, 40(3), 463-469.
168. Fabry, U., Körholz, D., Jurgens, H., Göbel, U., & Wahn, V. (1985). Anaphylaxis to l-asparaginase during treatment for acute lymphoblastic leukemia in children - evidence of a complement-mediated mechanism. Pediatric Research, 19(4), 400-408.
169. Baldo, B. A. (1990). Immunochemical perspectives of allergy: in the steps of Karl Landsteiner. In B. A. Baldo (Ed.), Monographs in allergy 28. Molecular approaches to the study of allergens (pp. 1-10). Basel: Karger.
170. Baldo, B. A., & Pham, N. H. (2013). Drug allergy. Clinical aspects, diagnosis, mechanisms, structure-activity relationships. New York: Springer.
171. Aster, R. H., & Bougie, D. W. (2007). Drug-induced immune thrombocytopenia. The New England Journal of Medicine, 357(6), 580-587.
172. Kenney, B., & Stack, G. (2009). Drug-induced thrombocytopenia. Archives of Pathology and Laboratory Medicine, 133(2), 309-314.
173. Wu, Y., Aravind, S., Ranganathan, G., Martin, A., & Nalysnyk, L. (2009). Anemia and thrombocytopenia in patients undergoing chemotherapy for solid tumors: a descriptive study of a large outpatient oncology practice database, 2000-2007. Clinical Therapeutics, 31(pt 2), 2416-2432.
174. Ten Berg, M. J., van den Bemt, P. M., Shantakumar, S., Bennett, D., Voest, E. E., Huisman, A., et al. (2011). Thrombocytopenia in adult cancer patients receiving chemotherapy: results from a retrospective hospital-based cohort study. Drug Safety, 34(12), 1151-1160.
175. Parikh, O., Neave, F., & Palmieri, C. (2008). Severe thrombocytopenia induced by a single infusion of trastuzumab. Clinical Breast Cancer, 8(3), 285-286.
176. Bautista, M. A., Stevens, W. T., Chen, C.-S., Curtis, B. R., Aster, R. H., & Hsueh, C.-T. (2010). Hypersensitivity reaction and acute immune-mediated thrombocytopenia from oxaliplatin: two case reports and a review of the literature. Journal of Hematology and Oncology, 3, 12.
177. Leach, M., Parsons, R. M., Reilly, J. T., & Winfield, D. A. (2000). Autoimmune thrombocytopenia: a complication of fludarabine therapy in lymphoproliferative disorders. Clinical & Laboratory Haematology, 22(3), 175-178.
178. Khatua, S., Nair, C. N., & Ghosh, K. (2004). Immune-mediated thrombocytopenia following dactinomycin therapy in a child with alveolar rhabdomyosarcoma: the unresolved issues. Journal of Pediatric Hematology/Oncology, 26(11), 777-779.
179. Mueller-Eckhardt, C., Kuenzlen, E., Kiefel, V., Vahrson, H., & Graubner, M. (1983). Cyclophosphamide-induced immune thrombocytopenia in a patient with ovarian carcinoma successfully treated with intravenous gamma globulin. Blut, 46(3), 165-169.
180. Seidman, A. D., Schwartz, M., Reich, L., & Scher, H. I. (1993). Immune-mediated thrombocytopenia secondary to suramin. Cancer, 71(3), 851-854.
181. Earle, C. C., Chen, W. Y., Ryan, D. P., & Mayer, R. J. (2001). Oxaliplatin-induced Evans syndrome. British Journal of Cancer, 84(3), 441.
182. Sørbye, H., Bruserud, Ø., & Dahl, O. (2001). Oxaliplatin-induced haematological emergency with an immediate severe thrombocytopenia and haemolysis. Acta Oncologica, 40(7), 882-883.
183. Overman, M. J., Maru, D. M., Charnsangavej, C., Loyer, E. M., Wang, H., Pathak, P., et al. (2010). Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury. Journal of Clinical Oncology, 28(15), 2549-2555.
184. Schouten, H. C. (2006). Neutropenia management. Annals of Oncology, 17(Suppl 10), 85-89.
185. Bhatt, V., & Saleem, A. (2004). Drug-induced neutropenia - pathophysiology, clinical features, and management. Annals of Clinical and Laboratory Science, 34(2), 131-137.
186. Berliner, N., Horwitz, M., & Loughran, T. P., Jr. (2004). Congenital and acquired neutropenia. Hematology American Society of Hematology Education Program, 1, 63-79.
187. Salama, A., Schütz, B., Kiefel, V., Breithaupt, H., & Mueller-Eckhardt, C. (1989). Immune-mediated agranulocytosis related to drugs and their metabolites: mode of sensitization and heterogeneity of antibodies. British Journal of Haematology, 72(2), 127-132.
188. Crawford, J., Dale, D. C., & Lyman, G. H. (2004). Chemotherapy-induced neutropenia. Risks, consequences, and new directions for its management. Cancer, 100(2), 228-237.
189. Garratty, G. (2009). Drug-induced immune hemolytic anemia. Hematology American Society of Hematology Education Program, 2009, 73-79.
190. Weiss, R. B., Freiman, J., Kweder, S. L., Diehl, L. F., & Byrd, J. C. (1998). Hemolytic anemia after fludarabine therapy for chronic lymphocytic leukemia. Journal of Clinical Oncology, 16(5), 1885-1889.
191. Gonzalez, H., Leblond, V., Azar, N., Sutton, L., Gabarre, J., Binet, J. L., et al. (1998). Severe autoimmune hemolytic anemia in eight patients treated with fludarabine. Hematology and Cell Therapy, 40(3), 113-118.
192. Tetreault, S. A., & Saven, A. (2000). Delayed onset of autoimmune hemolytic anemia complicating cladribine therapy for Waldenström macroglobulinemia. Leukemia and Lymphoma, 37(1-2), 125-130.
193. Getaz, E. P., Beckley, S., Fitzpatrick, J., & Dozier, A. (1980). Cisplatin-induced hemolysis. The New England Journal of Medicine, 302(6), 334-335.
194. Maloisel, F., Kurtz, J. E., Andres, E., Gorodetsky, C., Dufour, P., & Oberling, F. (1995). Platin salts-induced hemolytic anemia: cisplatin and the first case of carboplatin-induced hemolysis. Anti-Cancer Drugs, 6(2), 324-326.
195. Marani, T. M., Trich, M. B., Armstrong, K. S., Ness, P. M., Smith, J., & Minniti, C. (1996). Carboplatin-induced immune hemolytic anemia. Transfusion, 36(11-12), 1016-1018.
196. Garufi, C., Vaglio, S., Brienza, S., Conti, L., D'Attino, R. M., Girelli, G., et al. (2000). Immunohemolytic anemia following oxaliplatin administration. Annals of Oncology, 11(4), 497.
197. Bastuji-Garin, S., Joly, P., Picard-Dahan, C., Bernard, P., Vaillant, L., Pauweis, C., et al. (1996). Drugs associated with bullous pemphigoid. A case-control study. Archives of Dermatology, 132(3), 272-276.
198. Carlson, J., Ng, B., & Chen, K. (2005). Cutaneous vasculitis update: diagnostic criteria, classification, epidemiology, etiology, pathogenesis, evaluation and prognosis. The American Journal of Dermatopathology, 27(6), 504-528.
199. Choi, H. K., Merkel, P. A., Walker, A. M., & Niles, J. L. (2000). Drug-associated antineutrophil cytoplasmic antibody-positive vasculitis: prevalence among patients with high titers of antimyeloperoxidase antibodies. Arthritis & Rheumatism, 43(2), 405-413.
200. Wong, M., Grossman, J., Hahn, B. H., & La Cava, A. (2008). Cutaneous vasculitis in breast cancer treated with chemotherapy. Clinical Immunology, 129(1), 3-9.
201. Drago, F., Arditi, M., & Rebora, A. (1990). Tamoxifen and purpuric vasculitis. Annals of Internal Medicine, 112(12), 965-966.
202. Takahashi, Y., Ebi, N., Yamaguchi, O., Fukusho, R., Sugimoto, Y., & Tsuruno, K. (2011). A case of cutaneous vasculitis caused by erlotinib treatment and a review of literature. [Article in Japanese]. Nihon Kokyūki Gakkai Zasshi, 49(9), 663-666.
203. Green, R. M., Schapel, G. J., & Sage, R. E. (1989). Cutaneous vasculitis due to cyclophosphamide therapy for chronic lymphocytic leukemia. Australian & New Zealand Journal of Medicine, 19(1), 55-57.
204. Cabuk, M., Inanir, I., Türkdoǧan, P., Ceylan, C., Deǧirmenci, M., Türel, A., et al. (2004). Cyclic lymphocytic vasculitis associated with chronic lymphocytic leukemia. Leukemia and Lymphoma, 45(4), 811-813.
205. Cohen, P., & Kurzrock, R. (1997). Mucocutaneous paraneoplastic syndromes. Seminars in Oncology, 24(3), 334-359.
206. Liu, A., Fanning, L., Chong, H., Fernandez, J., Sloane, D., Sancho-Serra, M., et al. (2011). Desensitization regimens for drug allergy: state of the art in the 21st century. Clinical & Experimental Allergy, 41(12), 1679-1689.
207. Santini, D., Tonini, G., Salerno, A., Vincenzi, B., Patti, G., Battistoni, F., et al. (2001). Idiosyncratic reaction after oxaliplatin infusion. Annals of Oncology, 12(1), 132-133.
208. Castleberry, R. P., Crist, W. M., Holbrook, T., Malluh, A., & Gaddy, D. (1981). The cytosine arabinoside (Ara-C) syndrome. Medical and Pediatric Oncology, 9(3), 257-264.
209. Apisamthanarax, N., & Duvic, M. (2000). Dermatologic complications of cancer chemotherapy. In R. C. Jr Bast, D. W. Kufe, R. E. Pollock, et al. (Eds.), Holland-Frei cancer medicine (5th ed., pp. 2271-2278). Hamilton: Decker.
210. Gonçalo, M., & Bruynzeel, D. P. (2008). Mechanisms in cutaneous drug hypersensitivity reactions. In H. Zhai, K.-P. Wilhelm, & H. I. Maibach (Eds.), Marzulli and Maibach's dermatotoxicology (7th ed., pp. 259-268). Boca Raton: CRC.
211. Susser, W. S., Whitaker-Worth, D. L., & Grant-Kels, J. M. (1999). Mucocutaneous reactions to chemotherapy. Journal of the American Academy of Dermatology, 40(3), 367-398.
212. Ailor, S. K., & Miles, S. C. (2008). Dermatologic toxicity. In M. C. Perry (Ed.), The chemotherapy sourcebook (4th ed., pp. 136-147). Philadelphia: Lippincott Williams & Wilkins.
213. Horn, T. D., Redd, J. V., Karp, J. E., Beschorner, W. E., Burke, P. J., & Hood, A. F. (1989). Cutaneous eruptions of lymphocyte recovery. Archives of Dermatology, 125(11), 1512-1517.
214. Johnson, T., Rapini, R., & Duvic, M. (1987). Inflammation of actinic keratosis from systemic chemotherapy. Journal of the American Academy of Dermatology, 17(2, pt 1), 192-197.
215. Harrist, T. J., Fine, J. D., Berman, R. S., Murphy, G. F., & Mihm, M. C., Jr. (1982). Neutrophilic eccrine hidradenitis. A distinctive type of neutrophilic dermatosis associated with myelogenous leukemia and chemotherapy. Archives of Dermatology, 118(4), 263-266.
216. Brehler, R., Reimann, S., Bonsmann, G., & Metze, D. (1997). Neutrophilic hidradenitis induced by chemotherapy involves eccrine and apocrine glands. The American Journal of Dermatopathology, 19(1), 73-78.
217. Kaplowitz, N. (2005). Idiosyncratic drug hepatotoxicity. Nature Reviews Drug Discovery, 4(6), 489-499.
218. Friis, H., & Andreasen, P. B. (1992). Drug-induced hepatic injury: an analysis of 1100 cases reported to the Danish Committee on Adverse Drug Reactions between 1978 and 1987. Journal of Internal Medicine, 232(2), 133-138.
219. Ramachandran, R., & Kakar, S. (2009). Histological patterns in drug-induced liver disease. Journal of Clinical Pathology, 62(6), 481-492.
220. Ju, C. (2005). Immunological mechanisms of drug-induced liver injury. Current Opinion in Drug Discovery & Development, 8(1), 38-43.
221. Castell, J. V., & Castell, M. (2006). Allergic hepatitis induced by drugs. Current Opinion in Allergy and Clinical Immunology, 6(4), 258-265.
222. Adams, D. H., Ju, C., Ramaiah, S. K., Uetrecht, J., & Jaeschke, H. (2010). Mechanisms of immune-mediated liver injury. Toxicological Sciences, 115(2), 307-321.
223. Saleh, F., Ko, H. H., Davis, J. E., Apiratpracha, W., Powell, J. J., Erb, S. R., et al. (2007). Fatal hepatitis C associated fibrosing cholestatic hepatitis as a complication of cyclophosphamide and corticosteroid treatment of active glomerulonephritis. Annals of Hepatology, 6(3), 186-189.
224. Ellis, S. J., Cleverley, J. R., & Müller, N. L. (2000). Drug-induced lung disease: high-resolution CT findings. American Journal of Roentgenology, 175(4), 1019-1024.
225. Wong, P., Leung, A. N., Berry, G. J., Atkins, K. A., Montoya, J. G., Ruoss, S. J., et al. (2001). Paclitaxel-induced hypersensitivity pneumonitis: radiographic and CT findings. American Journal of Roentgenology, 176(3), 718-720.
226. Agache, I. O., & Rogozea, L. (2013). Management of hypersensitivity pneumonitis. Clinical and Translational Allergy, 3, 5. doi: 10.1186/2045-7022-3- 5.
227. Epler, G. (2011). Bronchiolitis obliterans organizing pneumonia (BOOP), 25 years: a variety of causes but what are the treatment options? Expert Review of Respiratory Medicine, 5(3), 353-361.
228. Schwaiblmair, M., Behr, W., Haeckel, T., Märkl, B., Foerg, W., & Berghaus, T. (2012). Drug-induced interstitial lung disease. The Open Respiratory Medicine Journal, 6, 63-74.
229. Etienne, B., Pérol, M., Nesme, P., Vuillermoz, S., Robinet, G., & Guérin, J. C. (1998). Acute diffuse interstitial pneumopathy following docetaxel (Taxotère). Apropos of 2 cases. [Article in French]. Revue des Maladies Respiratoires, 15(2), 199-203.
230. Limper, A. H. (2004). Chemotherapy-induced lung disease. Clinics in Chest Medicine, 25(1), 53-64.
231. Kressel, B. R., Ryan, K. P., Duong, A. T., Berenberg, J., & Schein, P. S. (1981). Microangiopathic hemolytic anemia, thrombocytopenia and renal failure in patients treated for adenocarcinoma. Cancer, 48(8), 1738-1745.
232. Zimmerman, S. E., Smith, F. P., Phillips, T. M., Coffey, R. J., & Schein, P. S. (1982). Gastric carcinoma and thrombocytic and thrombocytopenic purpura: association with plasma immune complex concentrations. British Medical Journal, 284(6327), 1432-1434.
233. Sheldon, R., & Slaughter, D. (1986). A syndrome of microangiopathic hemolytic anemia, renal impairment, and pulmonary edema in chemotherapy-treated patients with adenocarcinoma. Cancer, 58(7), 1428-1436.
234. Common terminology criteria for adverse events v3.0, DTCD, NCI, NIH, DHHS. Publish date: August 9, 2006. http://ctep.cancer.gov
235. Tonini, G., Santini, D., Vincenzi, B., Bortzomati, D., Dicuonzo, G., La Cesa, A., et al. (2002). Oxaliplatin may induce cytokine-release syndrome in colorectal cancer patients. Journal of Biological Regulators & Homeostatic Agents, 16(2), 105-109.
236. Howard, S. C., Jones, D. P., & Pui, C.-H. (2011). The tumor lysis syndrome. The New England Journal of Medicine, 364(19), 1844-1854.
237. Zanotti, K. M., Rybicki, L. A., Kennedy, A. W., Belinson, J. L., Webster, K. D., Kulp, B., et al. (2001). Carboplatin skin testing: a skin-testing protocol for predicting hypersensitivity to carboplatin chemotherapy. Journal of Clinical Oncology, 19(12), 3126-3129.
238. Markman, M., Zanotti, K., Peterson, G., Kulp, B., Webster, K., & Belinson, J. (2003). Expanded experience with an intradermal skin test to predict for the presence or absence of carboplatin hypersensitivity. Journal of Clinical Oncology, 21(24), 4611-4614.
239. Gomez, R., Harter, P., Lück, H. J., Traut, A., Kommoss, S., Kandel, M., et al. (2009). Carboplatin hypersensitivity: does introduction of skin test and desensitization reliably predict and avoid the problem? A prospective single-center study. International Journal of Gynecological Cancer, 19(7), 1284-1287.
240. Gastaminza, G., de la Borbolla, J. M., Goikoetxea, M. J., Escudero, R., Antón, J., Espinós, J., et al. (2011). A new rapid desensitization protocol for chemotherapy agents. Journal of Investigational Allergology and Clinical Immunology, 21(2), 108-112.
241. Meyer, L., Zuberbier, T., Worm, M., Oettle, H., & Riess, H. (2002). Hypersensitivity reactions to oxaliplatin: cross-reactivity to carboplatin and the introduction of a desensitization schedule. Clinical Oncology, 20(4), 1146-1147.
242. Reese, J. A., Li, X., Hauben, M., Aster, R. H., Bougie, D. W., Curtis, B. R., et al. (2010). Identifying drugs that cause acute thrombocytopenia: an analysis using 3 distinct methods. Blood, 116(12), 2127-2133.
243. Arnold, D. M., Santoso, S., Greinacher, A., & on behalf of the Platelet Immunology Scientific Subcommittee of the ISTH. (2012). Recommendations for the implementation of platelet autoantibody testing in clinical trials of immune thrombocytopenia. Journal of Thrombosis and Haemostasis, 10(4), 695-697.
244. Stroncek, D. F. (1993). Drug-induced immune neutropenia. Transfusion Medicine Reviews, 7(4), 268-274.
245. Borthakur, G., O'Brien, S., Wierda, W. G., Thomas, D. A., Cortes, J. E., Giles, F. J., et al. (2007). Immune anaemias in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide and rituximab - incidence and predictors. British Journal of Haematology, 136(6), 800-805.
246. Radić, M., Martinović Kaliterna, D., & Radić, J. (2012). Drug-induced vasculitis: a clinical and pathological review. Netherlands Journal of Medicine, 70(1), 12-17.
247. Matsuno, O. (2012). Drug-induced interstitial lung disease: mechanisms and best diagnostic approaches. Respiratory Research, 13, 39. doi: 10.1186/1465-9921-13-39.
248. Guilhot, F. (2004). Indications for imatinib mesylate therapy and clinical management. The Oncologist, 9(3), 271-281.
249. Guastalla, J. P., III, & Diéras, V. (2003). The taxanes: toxicity and quality of life considerations in advanced ovarian cancer. British Journal of Cancer, 89(Suppl 3), S16-S22.
250. Lee, C. W., Matulonis, U. A., & Castells, M. C. (2004). Carboplatin hypersensitivity: a 6-h 12-step protocol effective in 35 desensitizations in patients with gynecological malignancies and mast cell/IgE-mediated reactions. Gynecologic Oncology, 95(2), 370-376.
251. Bar-Sela, G., Kedem, E., Hadad, S., Pollack, S., Haim, N., Atrash, F., et al. (2010). Successful desensitization protocol for hypersensitivity reaction caused by sunitinib in a patient with a gastrointestinal stromal tumor. Japanese Journal of Clinical Oncology, 40(2), 163-165.
252. Chou, V., McClelland, S., Resnick, D. J., & Lee-Wong, M. (2005). Successful desensitization of an adult with type I hypersensitivity to imatinib. Internet Journal of Asthma, Allergy and Immunology, 4(2). doi: 10.5580/1a78.
253. Nelson, R. P., Jr., Cornetta, K., Ward, K. E., Ramanula, S., Fausel, C., & Cripe, L. D. (2006). Desensitization to imatinib in patients with leukemia. Annals of Allergy, Asthma & Immunology, 97(2), 216-222.
254. Kerbel, R. S. (2000). Tumor angiogenesis: past, present and the near future. Carcinogenesis, 21(3), 505-515.
255. Kerbel, R. S., Yu, J., Tran, J., Man, S., Viloria-Petit, A., Klement, G., et al. (2001). Possible mechanisms of acquired resistance to anti-angiogenic drugs: implications for the use of combination therapy approaches. Cancer Metastasis Reviews, 20(1-2), 79-86.
256. Bergers, G., & Hanahan, D. (2008). Modes of resistance to anti-angiogenic therapy. Nature Reviews Cancer, 8(8), 592-603.
257. Pàez-Ribes, M., Allen, E., Hudock, J., Takeda, T., Okuyama, H., Vinals, F., et al. (2009). Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell, 15(3), 220-231.
258. Ebos, J. M. L., Lee, C. R., Cruz-Munoz, W., Bjarnason, G. A., Christensen, J. G., & Kerbel, R. S. (2009). Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell, 15(3), 232-239.
259. Ebos, J. M. L., Lee, C. R., Christensen, J. G., Mutsaers, A. J., & Kerbel, R. S. (2007). Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. Proceedings of the National Academy of Sciences of the United States of America, 104(43), 17069-17074.
260. Kerbel, R. S. (2008). Tumor angiogenesis. The New England Journal of Medicine, 358(19), 2039-2049.
261. Baluk, P., Hashizume, H., & McDonald, D. M. (2005). Cellular abnormalities of blood vessels as targets in cancer. Current Opinion in Genetics and Development, 15(1), 102-111.
262. Semenza, G. L. (2003). Targeting HIF-1 for cancer therapy. Nature Reviews Cancer, 3(10), 721-732.
263. Jain, R. K. (2005). Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science, 307(5706), 58-62.
264. Galluzzo, M., Pennacchietta, S., Rosano, S., Comoglio, P. M., & Michieli, P. (2009). Prevention of hypoxia by myoglobin expression in human tumor cells promotes differentiation and inhibits metastasis. The Journal of Clinical Investigation, 119(4), 865-875.
265. Rapisarda, A., & Melillo, G. (2012). Overcoming disappointing results with amtiangiogenic therapy by targeting hypoxia. Nature Reviews. Clinical Oncology, 9(7), 378-390.
266. Harris, A. L. (2002). Hypoxia - a key regulatory factor in tumour growth. Nature Reviews Cancer, 2(1), 38-47.
267. Semenza, G. L. (2007). Hypoxia and cancer. Cancer Metastasis Reviews, 26(2), 223-224.
268. Maione, F., Molla, F., Meda, C., Latini, R., Zentilin, L., Giacca, M., et al. (2009). Semaphorin 3A is an endogenous angiogenesis inhibitor that blocks tumor growth and normalizes tumor vasculature in transgenic mouse models. The Journal of Clinical Investigation, 119(11), 3356-3372.
269. Maione, F., Capano, S., Regano, D., Zentilin, L., Giacca, M., Casanovas, O., et al. (2012). Semaphorin 3A overcomes cancer hypoxia and metastatic dissemination induced by antiangiogenic treatment in mice. The Journal of Clinical Investigation, 122(5), 1832-1848.
270. Rankin, E. B., & Giaccia, A. J. (2008). The role of hypoxia-inducible factors in tumorigenesis. Cell Death and Differentiation, 15(4), 678-685.
271. Muratori, C., & Tamagnone, L. (2012). Semaphorin signals tweaking the tumor microenvironment. In I. O. Daar (Ed.), Guidance molecules in cancer and tumor angiogenesis. Advances in cancer research, vol. 114 (pp. 59-87). San Diego: Academic.
272. Nam, S. Y., Ko, Y. S., Jung, J., Yoon, J., Kim, Y. H., Choi, Y. J., et al. (2011). A hypoxia-dependent upregulation of hypoxia-inducible factor-1 by nuclear factor-κB promotes gastric tumour growth and angiogenesis. British Journal of Cancer, 104(1), 166-174.
273. Birchmeier, C., Birchmeier, W., Gherardi, E., & Vande Woude, G. F. (2003). Met, metastasis, motility and more. Nature Reviews Molecular Cell Biology, 4(12), 915-925.
274. Giaccia, A., Siim, B. G., & Johnson, R. S. (2003). HIF-1α as a target for drug development. Nature Reviews Drug Discovery, 2(10), 803-811.
275. Welsh, S. J., & Powis, G. (2003). Hypoxia inducible factor as a cancer drug target. Current Cancer Drug Targets, 3(6), 391-405.
276. Rapisarda, A., Zalek, J., Hollingshead, M., Braunswchweig, T., Uranchimeg, B., Bonomi, C. A., et al. (2004). Schedule-dependent inhibition of hypoxia inducible factor-1 alpha protein accumulation, angiogenesis, and tumor growth by topotecan in U251-HRE glioblastoma xenografts. Cancer Research, 64(19), 6845-6848.
277. Vredenburgh, J. J., Desjardins, A., Herndon, J. E., Marcello, J., Reardon, D. A., Quinn, J. A., et al. (2007). Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. Journal of Clinical Oncology, 25(30), 4722-4729.
278. Rapisarda, A., & Melillo, G. (2009). Role of the hypoxic tumor microenvironment in the resistance to antiangiogenic therapies. Drug Resistance Update, 12(3), 74-80.
279. Rapisarda, A., & Melillo, G. (2012). Role of the VEGF/VEGFR axis in cancer biology and therapy. In I. O. Daar (Ed.), Guidance molecules in cancer and tumor angiogenesis. Advances in cancer research, vol. 114 (pp. 237-267). San Diego: Academic.
280. Pencreach, E., Guérin, E., Nicolet, C., Lelong-Rebel, I., Voegeli, A.-C., Oudet, P., et al. (2009). Marked activity of irinotecan and rapamycin combination toward colon cancer cells in vivo and in vitro is mediated through cooperative modulation of the mammalian target of rapamycin/hypoxia-inducible factor-1α axis. Clinical Cancer Research, 15(4), 1297-1307.
281. You, W.-K., Sennino, B., Williamson, C. W., Falcón, B., Hashizume, H., Yao, L.-C., et al. (2011). VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer. Cancer Research, 71(14), 4758-4768.
282. Avastin®. FDA: full prescribing information. Adverse reactions. http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/125085s0238lbl.pdf Accessed August 10, 2013.
283. Inlyta®. FDA: full prescribing information. Adverse reactions. http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/202324lbl.pdf. Accessed August 10, 2013.
284. Miranda, E., Nordgren, I. K., Male, A. L., Lawrence, C. E., Hoakwie, F., Cuda, F., et al. (2013). A cyclic peptide inhibitor of HIF-1 heterodimerization that inhibits hypoxia signaling in cancer cells. Journal of the American Chemical Society, 135(28), 10418-10425.
285. Holash, J. (2002). VEGF-Trap: a VEGF blocker with potent antitumor effects. Proceedings of the National Academy of Sciences of the United States of America, 99(17), 11393-11398.
286. Koh, Y. J., Kim, H. Z., Hwang, S.-I., Lee, J. E., Oh, N., Jung, K., et al. (2010). Double antiangiogenic protein, DAAP, targeting VEGF-A and angiopoietins in tumor angiogenesis, metastasis, and vascular leakage. Cancer Cell, 18(2), 171-184.
287. Fischer, C., Jonckx, B., Mazzone, M., Zacchigna, S., Loges, S., Pattarini, L., et al. (2007). Anti-PlGF inhibits growth of VEGF(R)-inhibitor- resistant tumors without affecting healthy vessels. Cell, 131(3), 463-475.
288. Cascone, T., & Heymach, J. V. (2012). Targeting the angiopoietin/Tie2 pathway: cutting tumor vessels with a double-edged sword? Journal of Clinical Oncology, 30(4), 441-444.
289. Tamburrino, A., Piro, G., Carbone, C., Tortora, G., & Melisi, D. (2013). Mechanisms of resistance to chemotherapeutic and anti-angiogenic drugs as novel targets for pancreatic cancer therapy. Frontiers in Pharmacology, 4, 56. doi: 10.3389/fphar.2013.00056.
290. Fingleton, B. (2006). Matrix metalloproteinases. Roles in cancer and metastasis. Frontiers in Bioscience, 11, 479-491.
291. Mas-Moruno, C., Rechenmacher, F., & Kessler, H. (2010). Cilengitide: the first anti-angiogenic small molecule drug candidate. Design, synthesis and clinical evaluation. Anti-Cancer Agents in Medicinal Chemistry, 10(10), 753-768.
292. Plate, K. H., Scholz, A., & Dumont, D. J. (2012). Tumor angiogenesis and anti-angiogenic therapy in malignant gliomas revisited. Acta Neuropathologica, 124(6), 763-775.
293. Garraty, G. (2010). Immune hemolytic anemia associated with drug therapy. Blood Reviews, 24(4-5), 143-150.